Trastuzumab Monoclonal Antibody

Trastuzumab (Herceptin) is a humanized monoclonal antibody that inhibits HER2 protein, used in HER2-positive breast cancer therapy. Classified under HTS 3002.13.0010 as an unmixed monoclonal antibody product from biotechnological processes, supplied in bulk for pharmaceutical compounding. It regulates immunological processes via antibody targeting as defined in Chapter 30 notes.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
🇨🇳ChinaFreeFree
🇲🇽MexicoFreeFree
🇨🇦CanadaFreeFree
🇩🇪GermanyFreeFree
🇯🇵JapanFreeFree

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

3002.15.00Same rate: Free

If in pre-measured vials for patient use

Dosage-form presentations for retail or clinical use move to 3002.15.

3002.90Higher: 10% vs Free

If complex mixture with other blood fractions

Products not purely unmixed monoclonal antibodies but combined with other fractions go to 3002.90.

9802.00.80Higher: 10% vs Free

If for US goods returned after biotech processing abroad

Articles assembled or processed abroad from US components may qualify for duty-free under 9802 if documented properly.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

Comply with USP <1046> cellular and tissue-based products standards if involving any cellular components

Provide biotech origin certificates and endotoxin testing results to avoid quarantine at ports

Label as 'not for retail sale' to prevent reclassification as consumer-packaged goods

Related Products under HTS 3002.13.00.10

Rituximab Monoclonal Antibody

Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used primarily for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.13.0010 as an unmixed immunological product consisting of monoclonal antibodies obtained via biotechnological processes, not put up in measured doses for retail sale. This classification applies to bulk pharmaceutical-grade preparations for further formulation.

Cetuximab Monoclonal Antibody

Cetuximab (Erbitux) targets EGFR for colorectal and head/neck cancer therapy, a chimeric monoclonal antibody. Bulk unmixed form imports under HTS 3002.13.0010 as a biotech immunological product per chapter note definitions. Excludes retail or dosed packings.

Infliximab Monoclonal Antibody

Infliximab (Remicade) is a chimeric monoclonal antibody neutralizing TNF-alpha for Crohn's disease and psoriasis. Classifies in HTS 3002.13.0010 for unmixed monoclonal immunological products from biotech, aligning with chapter's peptide/protein definition. Bulk for further processing.

Nivolumab Monoclonal Antibody

Nivolumab (Opdivo) human monoclonal antibody inhibits PD-1 for cancer immunotherapy applications. Bulk unmixed under HTS 3002.13.0010 as per immunological product notes for biotech proteins. Not in measured or retail forms.

Omalizumab Monoclonal Antibody

Omalizumab (Xolair) recombinant humanized monoclonal antibody binds IgE for severe asthma treatment. HTS 3002.13.0010 for unmixed monoclonal immunologicals from biotech processes. Bulk pharmaceutical grade.

Denosumab Monoclonal Antibody

Denosumab (Prolia) fully human monoclonal antibody inhibiting RANKL for osteoporosis. Classifies unmixed under HTS 3002.13.0010 per chapter immunological definitions. Bulk for formulation.